The timeframe for seeing changes varies from person to person
After 1 week of treatment, Fc-GLP1-injected mice showed an attenuated loss of body weight (11.0 0.46% versus 19.2 1.02) and adiposity compared to mice receiving G49 (Fig
Science 252 , 17081711 (1991)
Novo Nordisks new oral GLP-1, Wegovy pill, is a once-daily pill offering comparable weight-loss results (an average of 13.6% of your body weight) to injectable Wegovy.^ ^Eligible patients lost an average of 13.6% of their body weight in a 64-week clinical trial evaluating 25 mg oral semaglutide compared to those on 2.4 mg injectable semaglutide who lost an average of 14.9% of their body weight in a 68-week clinical trial
The first one was taken at base line, while the second was taken from the nearest point to the first one after stoppage of treatment (3 months after start of treatment)
Knowing your genetic profile helps you and your prescriber make informed decisions about timing, dosing, and whether combination therapies might suit your metabolic needs
